Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin
โ Scribed by Mark A. Rettenmaier; Mark F. Moran; Nilam F. Ramsinghani; Martin Colman; Nissar A. Syed; Amel Puthawala; Frederick W. Jansen; Philip J. Disaia
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 351 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Twelve patients with primary or locally recurrent squamous carcinoma of the cervix were treated with constant internal iliac artery infusion of cisplatin (CDDP) via a totally implantable chemotherapy pump. Seven previously untreated patients received standard external and interstitial radiotherapy (RT) in conjunction with CDDP infusion. Five patients with isolated pelvic recurrences received CDDP therapy only. The chemotherapy pump was refilled weekly on an outpatient basis. All nine evaluable patients developed unilateral or bilateral lower extremity pain which responded to dosage reduction. No renal or marrow toxicity was seen. Both of the evaluable patients treated for recurrent tumor died 32 and 60 weeks after initiation of treatment. The seven patients treated primarily with RT + CDDP infusion include one who expired with persistent tumor and one with no evidence of disease (NED) after exenteration for a pelvic recurrence at 48 and 85 weeks respectively. The five remaining patients are NED at 12 to 60 weeks. Constant internal iliac artery infusion of CDDP via an implantable chemotherapy pump can be performed with acceptable toxicity. The preliminary results suggest that further study in previously untreated undergoing concurrent radiotherapy is warranted.
๐ SIMILAR VOLUMES
City Uni-11 cases, for an overall response rate of 50%. Patients with good performance versity Medical School, Osaka, Japan. status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferenti-2 Insti
## Phase II Trial of Weekly Locoregional Hyperthermia and Cisplatin in Patients with a Previously Irradiated Recurrent Carcinoma of the Uterine Cervix BACKGROUND. The biologic rationale for combining cisplatin with locoregional Ron C
## Background: Patients with metastatic carcinoma of the uterine cervix have limited survival. thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. ## Methods: Twenty-seven patients with stage iv primary or recurrent carcinoma of the uterine cervix were assign